Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04799418 · ClinicalTrials.gov registry record · NA

STEM-PD Open Label Extension (OLE)

A NA study, sponsored by Scion NeuroStim.

Terminated
Registry status
NA
Development phase
148
Enrollment target

NCT04799418: Clinical Trial NA study, sponsored by Scion NeuroStim.

NCT04799418 is a NA study that was terminated before completion, run by Scion NeuroStim. The registered enrollment target is 148 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04799418, a NA study, was terminated before completion, sponsored by Scion NeuroStim.

TERMINATED
Registry status
NA
Development phase
148 participants
Enrollment target

Study Summary

This study seeks to establish the safety and efficacy of extended twice daily time-varying caloric vestibular stimulation treatments for treating symptoms associated with Parkinson's disease. Only participants who completed the STEM-PD randomized controlled trial portion (NCT04797611) are eligible to participate in the open label extension portion.

Primary Outcome

The primary endpoint is the change in MDS-NMS total score during the first treatment period during the open label extension (OLE) relative to the score at the end of the NCT04797611 randomized controlled trial (RCT) treatment period (day 113) for the passive-active treatment group compared to the change in MDS-NMS total score during the RCT treatment period relative to the pretreatment baseline. The MDS-NMS is 52-item rater-administered scale used to assess a wide range of non-motor symptoms in

Interventions

  • DEVICE Open Label Extension Study

Trial Details

FieldValue
Enrollment Target 148 participants
Start Date 2022-09-15
Est. Completion 2025-02-24
Phase NA
Scion NeuroStim

9 total trials

Why NCT04799418 stopped before completion

NCT04799418 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 1 intervention - of which Open Label Extension Study is the first listed.

NCT04799418 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04799418 about?

NCT04799418 is a clinical study titled "STEM-PD Open Label Extension (OLE)". This study seeks to establish the safety and efficacy of extended twice daily time-varying caloric vestibular stimulation treatments for treating symptoms associated with Parkinson's disease. Only participants who completed the STEM-PD randomized controlled trial portion (NCT04797611) are eligible t...

What is the current status of trial NCT04799418?

This trial is currently terminated. It is a NA study. The enrollment target is 148 participants. The study started on 2022-09-15. Estimated completion is 2025-02-24.

What interventions are being tested in trial NCT04799418?

The interventions under investigation include: Open Label Extension Study (DEVICE).

Who is sponsoring clinical trial NCT04799418?

This trial is sponsored by Scion NeuroStim, which has 9 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04799418's enrollment target sits among peer trials

148 702nd of 2000 higher than 1,298 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00739362 · 148 participants · Phase 2

    Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment

  • NCT03161223 · 148 participants · Phase 1

    Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

  • NCT03858231 · 148 participants · Phase 4

    Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery

  • NCT04486352 · 148 participants · Phase 1

    A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04799418, the US trial registry maintained by the National Library of Medicine. NCT04799418 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.